APA

Discafani C. M., Carroll M. L., Floyd M. B., Hollander I. J., Husain Z., Johnson B. D., Kitchen D., May M. K., Malo M. S., Minnick A. A., Nilakantan R., Shen R., Wang Y. F., Wissner A. & Greenberger L. M. (19990401). Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785). : Biochemical pharmacology.

Chicago

Discafani C M, Carroll M L, Floyd M B, Hollander I J, Husain Z, Johnson B D, Kitchen D, May M K, Malo M S, Minnick A A, Nilakantan R, Shen R, Wang Y F, Wissner A and Greenberger L M. 19990401. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785). : Biochemical pharmacology.

Harvard

Discafani C. M., Carroll M. L., Floyd M. B., Hollander I. J., Husain Z., Johnson B. D., Kitchen D., May M. K., Malo M. S., Minnick A. A., Nilakantan R., Shen R., Wang Y. F., Wissner A. and Greenberger L. M. (19990401). Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785). : Biochemical pharmacology.

MLA

Discafani C M, Carroll M L, Floyd M B, Hollander I J, Husain Z, Johnson B D, Kitchen D, May M K, Malo M S, Minnick A A, Nilakantan R, Shen R, Wang Y F, Wissner A and Greenberger L M. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785). : Biochemical pharmacology. 19990401.